Az Sint-Lucas & Volkskliniek — Clinical Trial Site

65 Registered trials

27 Currently recruiting

Organisation

Az Sint-Lucas & Volkskliniek

Location

Gent, Belgium

Identifier

ORG-100041035

Address

Groenebriel 1, 9000, Belgium

Departments

0504: longziekten
7110: AZ Sint-Lucas - Campus Sint-Lu
Cardiology
Center for Reproductive Medicine
Department of Cardiology
Department of Dermatology
Department of Oncology
Department Pneumology/Respiratory Oncology
Dermatology
Gastro-enterologie
Gastro-enterology
Gastroenterology
Hart- en vaatziekten
Intensive care unit
Maag-, darm- en leverziekten
Medical Oncology
N/A
NA
Neurology
Neurology department
Oncology
Pneumologie
radiotherapy
Study center Oncology

Clinical trials at this site (65)

Search interface

ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended

2023-509087-20-00 Metastatic Castration-resistant Prostate Cancer 5 2019-04-16
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase II/III Study of ABC008 to Determine Efficacy and Safety in IBM Ended

2022-501925-19-00 inclusion body myositis 10 2024-01-17
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe… Ended

2023-510317-26-00 Amyotrophic Lateral Sclerosis 4 2023-02-07
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon… Ended

2023-506981-30-00 Chronic kidney disease in type 2 diabetes mellitus 4 2022-05-25
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended

2024-511140-37-00 OligoRecurrent prostate cancer 4 2021-02-12
Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended

2022-501972-25-00 Locally Advanced Cervical Cancer 5 2020-04-06
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5
A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons… Ended

2024-515393-27-00 Nonsquamous non-small cell lung cancer 4